Abstract
To compare the cost-effectiveness of prescribing biologics (secukinumab, golimumab, certolizumab pegol, ustekinumab, adalimumab, etanercept, and infliximab including biosimilars) for adult bio naïve patients with active psoriatic arthritis in Russia. Based on data on the efficacy of compared treatment regimens, data on the cost of drugs and medical services, as well as the frequency of their provision the cost-effectiveness analysis was carried out. According to national requirements for performance of cost-effectiveness results, we demonstrated difference (%) in the cost-effectiveness ratio between analysed treatment options. The study had a time horizon of 3 years. The discount rate was 3% per year. The evaluation of therapy effectiveness was based on ACR 20/50/70 response criteria. Cost-effectiveness ratio of secukinumab is on average 65% and 55% lower than the cost-effectiveness ratio of treatment with certolizumab pegol, golimumab, ustekinumab, adalimumab, etanercept and infliximab in the first and subsequent years of therapy, in accordance. Estimation of costs and efficacy showed that treatment with secukinumab is characterised by lower costs per unit of efficacy (ACR 20/50/70 response), relative to the indicators of the compared drugs in the first and subsequent years of therapy adult bio naïve patients with active psoriatic arthritis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
